Why the study?
Does the CHA2DS2-VASc score identify patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy?
Does the CHA2DS2-VASc score identify patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy?
The CHA2DS2-VASc score can identify a subset of AF patients with a CHADS2 score of 1 who have a low enough stroke risk (1% annually) to potentially withhold oral anticoagulation.
Answers are grounded in this paper and cite their sources.
Should not yet alter OAC thresholds on CHA2DS2-VASc reclassification alone; leaves open prospective validation in AF cohorts.
The CHA(2)DS(2)-VASc score reclassifies 26% of patients with a CHADS(2) score of 1 to a low annual risk of SSE of 1%. This risk seems low enough to consider withholding anticoagulant treatment.
No takes yet. Share an insight, caveat, or question.
Coppens et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: